About this Webinar
During this webinar, our analysts will assess recent FDA and EMA pharmaceutical approvals, including COVID-19 therapeutics and vaccines.
The webinar will last approximately 30 minutes and will cover:
- Identify the trends among novel drugs, from disease indication to Molecule Type, and hear what they mean for the future of the pharmaceutical industry.
- Learn the factors influencing Bio/Pharmaceutical companies' outsourcing of these approvals.
Speakers
Fiona Barry
Fiona Barry, MA, is the Associate Editor of PharmSource, responsible for PharmSource’s editorial content and the publication of PharmSource’s Trend Reports, monthly Bio/Pharmaceutical Outsourcing Reports, and quarterly Emerging Market Outsourcing Reports. Fiona previously worked as an investigative journalist for GlobalData’s drug development news service, formerly BioPharm Insight, reporting scoops on clinical trials, contract pharma, rare diseases, and women’s health. She is also an experienced financial journalist and a frequent expert speaker at pharmaceutical industry conferences. Fiona worked for several years as a reporter at William Reed Business Media’s French office, breaking global manufacturing, regulatory, and outsourcing news for the biopharmaceutical industry for in-PharmaTechnologist, Outsourcing-Pharma, and BioPharma Reporter. She holds an MA in English and a BA in English and Philosophy from the University of Bristol, UK.
Quentin Horgan
Quentin Horgan, MSc, BSc is a managing Drugs Analyst at GlobalData. Quentin is responsible for the enhancement of the Drugs database, including the reviewing and updating of drug information presented on GlobalData’s drug module, as well as the maintenance of data quality through quality control
and timely client support. Quentin also supports sales team members in addition to working with and coordinating teams globally. He has a firm understanding of all aspects of the pharmaceutical market, drugs development, and marketing. Quentin holds a MSc in Drugs Discovery and Pharma Management from University College London and a BSc in Biochemistry from the University of Sussex.
Camila Dalitz
Camila Dalitz, MSc, BSc is a Drugs Analyst at GlobalData in London. Camila's primary responsibilities include maintaining GlobalData's Drugs Database, reviewing and updating drug information, and providing timely client and sales support. Camila is also responsible for testing database releases, producing analytical reports, and database quality checking. Prior to joining GlobalData, Camila worked as a Senior Business Analyst at Evalueserve Chile, and as a Multilingual Medical Information Specialist at ProPharma Group. Camila holds an MSc in Microbiology and a BSc in Biology from Federal University of Paraná, Brazil.
Past Webinars
View more past webinarsUpcoming Webinars
View more upcoming webinarsSearch companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer


